Publicaciones en colaboración con investigadores/as de Hospital Universitario de Valme (9)

2024

  1. Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease

    Gut, Vol. 73, Núm. 5, pp. 825-834

  2. Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)

    Hepatology, Vol. 79, Núm. 1, pp. 135-148

  3. The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis

    Journal of Gastroenterology, Vol. 59, Núm. 7, pp. 586-597

2022

  1. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: Time for reappraisal of BMI-driven approach?

    Gut, Vol. 71, Núm. 2, pp. 382-390

  2. Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation

    Scientific Reports, Vol. 12, Núm. 1

  3. Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles

    Hepatology, Vol. 76, Núm. 4, pp. 1121-1134

2021

  1. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects

    Liver International, Vol. 41, Núm. 9, pp. 2076-2086

  2. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease

    Journal of Hepatology, Vol. 75, Núm. 4, pp. 786-794

2018

  1. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study

    Gastroenterology, Vol. 155, Núm. 2, pp. 443-457.e17